Datamonitor interviewed a psychiatrist based in Boston, MA to determine their current treatment practices and opinions on late-stage pipeline drugs for the treatment of schizophrenia.

If you are a KOL Insight Subscriber, please access this report here, in our KOL Insight portal (Subscribers only).

Highlights

• KOL believes that the available schizophrenia treatments that provide the most efficacy also have the highest side effects.
• Abilify Maintena, Risperdal Consta, and Invega Sustenna are the main long-acting injectables (LAIs) he uses (Outsuka, JNJ), but US LAI use overall is low (5%).
• There’s nothing that differentiates Vraylar (cariprazine) from other currently available treatments (AGN/PFE).
• Patients have to be on four months of Invega Sustenna before considering switching to Trinza so its use will only be for a small set up non-compliant patients; Trinza will not take the place of Sustenna (JNJ).
• KOL feels that the partial clinical hold due to safety issues is a huge hurdle for Encenicline to overcome (FORUM).
• Acadia drug, Nuplazid (pimavanserin), is worth looking into for Parkinson’s Disease Psychosis (ACAD).

BioMedTracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.

For our disclosures, please read the BioMedTracker Research Standards.